On the public citation graph
Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome
0 signed · 561 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/archinte.162.22.2597openalex-snapshot
Diabetes, Plasma Insulin, and Cardiovascular Disease
inferredcites →https://doi.org/10.1001/archinte.165.10.1154openalex-snapshot
Bezafibrate for the Secondary Prevention of Myocardial Infarction in Patients With Metabolic Syndrome
inferredcites →https://doi.org/10.1001/jama.269.23.3015openalex-snapshot
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
inferredcites →https://doi.org/10.1001/jama.285.19.2486openalex-snapshot
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
inferredcites →https://doi.org/10.1001/jama.298.3.299openalex-snapshot
Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women
inferredcites →https://doi.org/10.1007/s00125-005-0063-9openalex-snapshot
Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes
inferredcites →https://doi.org/10.1016/s0140-6736(05)67667-2openalex-snapshot
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
inferredcites →https://doi.org/10.1016/s0140-6736(08)60104-xopenalex-snapshot
Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis
inferredcites →https://doi.org/10.1016/s0140-6736(08)60602-9openalex-snapshot
Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies
inferredcites →https://doi.org/10.1016/s0140-6736(08)60731-xopenalex-snapshot
Metabolic syndrome—what is the clinical usefulness?
inferredcites →https://doi.org/10.1038/ijo.2008.29openalex-snapshot
Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study
inferredcites →https://doi.org/10.1038/ijo.2008.30openalex-snapshot
Cardiometabolic risk: a Framingham perspective
inferredcites →https://doi.org/10.1097/00043798-199604000-00014openalex-snapshot
Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies
inferredcites →https://doi.org/10.1097/01.hpc.0000086202.17560.4bopenalex-snapshot
PROVE-IT TIMI 22 Study
inferredcites →https://doi.org/10.1159/000468530openalex-snapshot
Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled Study
inferredcites →https://doi.org/10.1161/01.cir.82.2.495openalex-snapshot
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.
inferredcites →https://doi.org/10.1161/01.cir.85.1.37openalex-snapshot
Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.
inferredcites →https://doi.org/10.1161/circulationaha.106.637793openalex-snapshot
Triglycerides and the Risk of Coronary Heart Disease
inferredcites →https://doi.org/10.1177/174182679600300214openalex-snapshot
Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies
inferredcites →https://doi.org/10.1186/1475-2840-3-9openalex-snapshot
The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]
inferredcites →https://doi.org/10.1186/1475-2840-4-13openalex-snapshot
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
inferredcites →https://doi.org/10.2337/dc07-0015openalex-snapshot
Fenofibrate Therapy Ameliorates Fasting and Postprandial Lipoproteinemia, Oxidative Stress, and the Inflammatory Response in Subjects With Hypertriglyceridemia and the Metabolic Syndrome
inferredcites →https://doi.org/10.2337/diabetes.52.5.1210openalex-snapshot
NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older
inferredcites →https://doi.org/10.2337/diacare.25.10.1790openalex-snapshot
Components of the Metabolic Syndrome and Risk of Cardiovascular Disease and Diabetes in Beaver Dam
inferredcites →https://doi.org/10.2337/diacare.28.2.385openalex-snapshot
The Metabolic Syndrome and 11-Year Risk of Incident Cardiovascular Disease in the Atherosclerosis Risk in Communities Study
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.5281/zenodo.8266551openalex-extracted
Fenofibrate: A novel approach in treating uncomplicated neonatal hyperbilirubinemia?
inferred← citeshttps://doi.org/10.1001/jamacardio.2016.4828openalex-snapshot
Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes
inferred← citeshttps://doi.org/10.1001/jamacardio.2025.0195openalex-snapshot
Joint Associations of APOC3 and LDL-C–Lowering Variants With the Risk of Coronary Heart Disease
inferred← citeshttps://doi.org/10.1001/jamainternmed.2014.1371openalex-snapshot
Descriptions and Interpretations of the ACCORD-Lipid Trial in the News and Biomedical Literature
inferred← citeshttps://doi.org/10.1002/0471266949.bmc191openalex-snapshot
Nuclear Hormone Receptor Medicinal Chemistry
inferred← citeshttps://doi.org/10.1002/0471266949.bmc191.pub2openalex-snapshot
Nuclear Hormone Receptor Medicinal Chemistry
inferred← citeshttps://doi.org/10.1002/14651858.cd009580openalex-snapshot
Fibrates for secondary prevention of cardiovascular disease and stroke
inferred← citeshttps://doi.org/10.1002/14651858.cd009580.pub2openalex-snapshot
Fibrates for secondary prevention of cardiovascular disease and stroke
inferred← citeshttps://doi.org/10.1002/2327-6924.12048openalex-snapshot
Metabolic syndrome: Clinical perspective for best practice
inferred← citeshttps://doi.org/10.1002/9781118158678.ch11openalex-snapshot
Enhancement of HDL Formation and Normalization of Intravascular HDL Remodeling
inferred← citeshttps://doi.org/10.1002/9781118337967.ch7openalex-snapshot
Dyslipidemia and Its Management in Type 2 Diabetes
inferred← citeshttps://doi.org/10.1002/9781118387658.ch17openalex-snapshot
Lipid and lipoprotein metabolism, hypolipidemic agents, and therapeutic goals
inferred← citeshttps://doi.org/10.1002/9781118387658.ch20openalex-snapshot
Treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
inferred← citeshttps://doi.org/10.1002/9781118494073.ch8openalex-snapshot
Statin Therapy in Patients with Diabetic Nephropathy
inferred← citeshttps://doi.org/10.1002/9781444340280.ch13openalex-snapshot
Are Statins the Optimal Therapy for Cardiovascular Risk in Patients with Diabetes? Are Triglycerides an Important Independent Risk Factor for Diabetes?
inferred← citeshttps://doi.org/10.1002/clc.20774openalex-snapshot
A Very High Prevalence of Low HDL Cholesterol in Spanish Patients With Acute Coronary Syndromes
inferred← citeshttps://doi.org/10.1002/cpt.1436openalex-snapshot
Trials in “True” Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk
inferred← citeshttps://doi.org/10.1002/dmrr.3163openalex-snapshot
Hypertriglyceridaemia predicts subsequent long‐term risk of cardiovascular events in Chinese adults: 23‐year follow‐up of the Daqing Diabetes Study
inferred← citeshttps://doi.org/10.1002/med.21349openalex-snapshot
Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies
inferred← citeshttps://doi.org/10.1002/pdi.1511openalex-snapshot
More than meets the eye: the ACCORD trial and use of statin‐fibrate combination in type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1002/pdi.1610openalex-snapshot
Hypertriglyceridaemia in statin‐treated type 2 diabetic patients
inferred← citeshttps://doi.org/10.1007/978-1-4614-7554-5_13openalex-snapshot
Endothelial Dysfunction and Dyslipidemia in Type 2 Diabetes: Pathogenesis, Significance and Therapy
inferred← citeshttps://doi.org/10.1007/978-1-4614-7554-5_17openalex-snapshot
About Randomised Clinical Trials Related to Lipoproteins in Diabetes Mellitus
inferred← citeshttps://doi.org/10.1007/978-1-4614-7554-5_20openalex-snapshot
Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients
inferred← citeshttps://doi.org/10.1007/978-1-4614-7554-5_23openalex-snapshot
Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes
inferred← citeshttps://doi.org/10.1007/978-3-030-11815-0_38openalex-snapshot
Diabetes and Atherogenic Dyslipidemia
inferred← citeshttps://doi.org/10.1007/978-3-030-36694-0_2openalex-snapshot
Diabetes and Dyslipidemia
inferred← citeshttps://doi.org/10.1007/978-3-030-56514-5_8openalex-snapshot
Triglyceride-rich Lipoprotein Cholesterol (Remnant Cholesterol) as a Therapeutic Target for Cardiovascular Disease Risk
inferred← citeshttps://doi.org/10.1007/978-3-030-98927-9_1openalex-snapshot
Precision Medicine Approaches for Management of Type 2 Diabetes
inferred← citeshttps://doi.org/10.1007/978-3-031-13177-6_23openalex-snapshot
Managing Stable Coronary Artery Disease in Diabetes
inferred← citeshttps://doi.org/10.1007/978-3-031-25519-9_40openalex-snapshot
Diabetes and Atherogenic Dyslipidemia
inferred← citeshttps://doi.org/10.1007/978-3-031-26681-2_20openalex-snapshot
About Randomized Clinical Trials Related to Lipoproteins in Diabetes Mellitus
inferred← citeshttps://doi.org/10.1007/978-3-031-26681-2_24openalex-snapshot
Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Patients with Diabetes Mellitus Type 2
inferred← citeshttps://doi.org/10.1007/978-3-031-26681-2_28openalex-snapshot
Clinical Care of Lipids in People with Type 1 Diabetes
inferred← citeshttps://doi.org/10.1007/978-3-031-82232-2_24openalex-snapshot
How to Evaluate and Reduce Micro- and/or Macrovascular Residual Risk?
inferred← citeshttps://doi.org/10.1007/978-3-319-12125-3_30-1openalex-snapshot
Dyslipidemia in Obesity
inferred← citeshttps://doi.org/10.1007/978-3-319-20433-8_5openalex-snapshot
The Role of Omega-3 Fatty Acids in Dyslipidemias
inferred← citeshttps://doi.org/10.1007/978-3-319-27316-7_2-1openalex-snapshot
Diabetes and Dislipidemia
inferred← citeshttps://doi.org/10.1007/978-3-319-27316-7_2-2openalex-snapshot
Diabetes and Dyslipidemia
inferred← citeshttps://doi.org/10.1007/978-3-319-27316-7_2-3openalex-snapshot
Diabetes and Dyslipidemia
inferred← citeshttps://doi.org/10.1007/978-3-319-27316-7_2-4openalex-snapshot
Diabetes and Dyslipidemia
inferred← citeshttps://doi.org/10.1007/978-3-319-44433-8_2openalex-snapshot
Diabetes and Dislipidemia
inferred← citeshttps://doi.org/10.1007/978-3-319-97622-8_7openalex-snapshot
Management of Diabetes Mellitus
inferred← citeshttps://doi.org/10.1007/s00125-010-1806-9openalex-snapshot
Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes
inferred← citeshttps://doi.org/10.1007/s00125-014-3344-3openalex-snapshot
Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
inferred← citeshttps://doi.org/10.1007/s00380-013-0330-5openalex-snapshot
Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol
inferred← citeshttps://doi.org/10.1007/s00508-016-0993-xopenalex-snapshot
Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications
inferred← citeshttps://doi.org/10.1007/s00592-009-0129-0openalex-snapshot
Exercise therapy in Type 2 diabetes
inferred← citeshttps://doi.org/10.1007/s10198-021-01280-6openalex-snapshot
Are regions equal in adversity? A spatial analysis of spread and dynamics of COVID-19 in Europe
inferred← citeshttps://doi.org/10.1007/s10354-011-0908-4openalex-snapshot
Lipid lowering therapy in type 2 diabetes
inferred← citeshttps://doi.org/10.1007/s10557-008-6160-5openalex-snapshot
More Clinical Lessons from the FIELD Study
inferred← citeshttps://doi.org/10.1007/s10557-009-6190-7openalex-snapshot
How Can We Improve the Management of Vascular Risk in Type 2 Diabetes: Insights from FIELD
inferred← citeshttps://doi.org/10.1007/s10557-011-6280-1openalex-snapshot
Long-Term Efficacy of Adding Fenofibric Acid to Moderate-Dose Statin Therapy in Patients with Persistent Elevated Triglycerides
inferred← citeshttps://doi.org/10.1007/s10557-012-6395-zopenalex-snapshot
Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial
inferred← citeshttps://doi.org/10.1007/s11154-010-9132-6openalex-snapshot
Management of dyslipidemia in people with type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1007/s11428-012-0894-1openalex-snapshot
Ernährung bei diabetischer Dyslipidämie
inferred← citeshttps://doi.org/10.1007/s11428-016-0176-4openalex-snapshot
Kardiovaskulär wirksame Therapie bei Patienten mit Diabetes mellitus
inferred← citeshttps://doi.org/10.1007/s11883-009-0043-5openalex-snapshot
Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease
inferred← citeshttps://doi.org/10.1007/s11883-010-0126-3openalex-snapshot
Fibrate Therapy in the Management of Diabetic Dyslipidemia: There is No ACCORD to be Found
inferred← citeshttps://doi.org/10.1007/s11883-010-0139-yopenalex-snapshot
Combination Lipid Therapy in Type 2 Diabetes
inferred← citeshttps://doi.org/10.1007/s11883-011-0162-7openalex-snapshot
Effects of Combination Lipid Therapy in Diabetes Mellitus
inferred← citeshttps://doi.org/10.1007/s11883-014-0429-xopenalex-snapshot
HDL: To Treat or Not To Treat?
inferred← citeshttps://doi.org/10.1007/s11883-020-00846-8openalex-snapshot
Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions
inferred← citeshttps://doi.org/10.1007/s11883-020-00897-xopenalex-snapshot
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
inferred← citeshttps://doi.org/10.1007/s11883-022-01012-yopenalex-snapshot
The Role of High-Density Lipoprotein Cholesterol in 2022
inferred← citeshttps://doi.org/10.1007/s11883-025-01379-8openalex-snapshot
Fibrates : Do They Still Have a Role in Therapy in 2025?
inferred← citeshttps://doi.org/10.1007/s11886-011-0220-3openalex-snapshot
The Role of Triglycerides in Atherosclerosis
inferred← citeshttps://doi.org/10.1007/s11886-011-0237-7openalex-snapshot
Do Persons with Diabetes Benefit from Combination Statin and Fibrate Therapy?
inferred← citeshttps://doi.org/10.1007/s11886-012-0305-7openalex-snapshot
Treatment Targets in the Management of Dyslipidemias: Which Targets in Whom?
inferred← citeshttps://doi.org/10.1007/s11886-012-0309-3openalex-snapshot
Management of Dyslipidemias in the Presence of the Metabolic Syndrome or Type 2 Diabetes
inferred← citeshttps://doi.org/10.1007/s11886-013-0400-4openalex-snapshot
How Do Elevated Triglycerides and Low HDL-Cholesterol Affect Inflammation and Atherothrombosis?
inferred← citeshttps://doi.org/10.1007/s11886-014-0512-5openalex-snapshot
Role of HDL in Those with Diabetes
inferred← citeshttps://doi.org/10.1007/s11886-015-0589-5openalex-snapshot
Role for Combination Therapy in Diabetic Dyslipidemia
inferred← citeshttps://doi.org/10.1007/s11886-017-0818-1openalex-snapshot
Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes
inferred← citeshttps://doi.org/10.1007/s11886-022-01831-0openalex-snapshot
Omega-3 Fatty Acids in Cardiovascular Disease and Diabetes: a Review of Recent Evidence
inferred← citeshttps://doi.org/10.1007/s11892-010-0124-4openalex-snapshot
Management of Hypertriglyceridemia in the Diabetic Patient
inferred← citeshttps://doi.org/10.1007/s11892-019-1136-3openalex-snapshot
Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes
inferred← citeshttps://doi.org/10.1007/s11926-020-00942-3openalex-snapshot
Lipid-lowering Therapies in Myositis
inferred← citeshttps://doi.org/10.1007/s11936-009-0027-3openalex-snapshot
Management of the statin-intolerant patient
inferred← citeshttps://doi.org/10.1007/s11936-011-0128-7openalex-snapshot
The Use of Fibric Acid Derivatives in Cardiovascular Prevention
inferred← citeshttps://doi.org/10.1007/s11936-012-0220-7openalex-snapshot
What should we do about Hypertriglyceridemia in Coronary Artery Disease Patients?
inferred← citeshttps://doi.org/10.1007/s12020-011-9530-xopenalex-snapshot
Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments
inferred← citeshttps://doi.org/10.1007/s12020-016-0939-0openalex-snapshot
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia
inferred← citeshttps://doi.org/10.1007/s12325-009-0045-2openalex-snapshot
Omacor® (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia
inferred← citeshttps://doi.org/10.1007/s12325-016-0462-yopenalex-snapshot
A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids
inferred← citeshttps://doi.org/10.1007/s12471-021-01600-8openalex-snapshot
Working towards full eradication of lipid-driven cardiovascular risk?
inferred← citeshttps://doi.org/10.1007/s13340-015-0225-zopenalex-snapshot
Treatment of dyslipidemia in diabetes. Should the lipid-management protocol which the ADA 2015 guideline recommends be used for Japanese as a reference?
inferred← citeshttps://doi.org/10.1007/s40265-013-0023-5openalex-snapshot
Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management
inferred← citeshttps://doi.org/10.1007/s40265-018-0965-8openalex-snapshot
Fenofibrate and Dyslipidemia: Still a Place in Therapy?
inferred← citeshttps://doi.org/10.1016/b978-0-12-391884-0.00028-7openalex-snapshot
Genetic Influences on Blood Lipids and Cardiovascular Disease Risk
inferred← citeshttps://doi.org/10.1016/b978-0-12-802928-2.00026-6openalex-snapshot
Genetic Influences on Blood Lipids and Cardiovascular Disease Risk
inferred← citeshttps://doi.org/10.1016/b978-0-323-28786-9.00027-xopenalex-snapshot
Combination Therapy for Dyslipidemia
inferred← citeshttps://doi.org/10.1016/b978-0-323-28786-9.00035-9openalex-snapshot
Special Patient Populations
inferred← citeshttps://doi.org/10.1016/b978-0-323-42880-4.00008-xopenalex-snapshot
Lipid Measurements
inferred← citeshttps://doi.org/10.1016/b978-0-323-42880-4.00024-8openalex-snapshot
Managing Chronic Coronary Artery Disease in Patients with Diabetes
inferred← citeshttps://doi.org/10.1016/b978-0-323-88286-6.00031-5openalex-snapshot
Special Patient Populations
inferred← citeshttps://doi.org/10.1016/b978-1-4377-1366-4.00015-9openalex-snapshot
The Contribution of Triglycerides and Triglyceride-Rich Lipoproteins to Atherosclerotic Cardiovascular Disease
inferred← citeshttps://doi.org/10.1016/b978-1-4377-1366-4.00022-6openalex-snapshot
Metabolic Syndrome and Cardiovascular Disease
inferred← citeshttps://doi.org/10.1016/b978-2-294-70868-8.50005-0openalex-snapshot
Désordres cliniques et biologiques associés
inferred← citeshttps://doi.org/10.1016/b978-2-294-70868-8.50008-6openalex-snapshot
Thérapeutique des désordres associés
inferred← citeshttps://doi.org/10.1016/b978-2-294-73954-5.00005-6openalex-snapshot
Désordres cliniques et biologiques associés
inferred← citeshttps://doi.org/10.1016/b978-2-294-73954-5.00008-1openalex-snapshot
Thérapeutique des désordres associés
inferred← citeshttps://doi.org/10.1016/b978-2-294-74646-8.00019-5openalex-snapshot
Diabète de type2 etdyslipidémie
inferred← citeshttps://doi.org/10.1016/b978-2-294-75889-8.00008-7openalex-snapshot
Thérapeutique des désordres associés
inferred← citeshttps://doi.org/10.1016/j.acvd.2020.04.004openalex-snapshot
The return of triglycerides and revival of omega-3 fatty acids!
inferred← citeshttps://doi.org/10.1016/j.ahj.2011.12.004openalex-snapshot
Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
inferred← citeshttps://doi.org/10.1016/j.ahj.2018.09.011openalex-snapshot
Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
inferred← citeshttps://doi.org/10.1016/j.amjcard.2012.04.003openalex-snapshot
Recent Clinical Studies of the Effects of Lipid-Modifying Therapies
inferred← citeshttps://doi.org/10.1016/j.amjmed.2009.03.030openalex-snapshot
Effect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review
inferred← citeshttps://doi.org/10.1016/j.amjmed.2011.08.025openalex-snapshot
The Cardiovascular Effects of Peroxisome Proliferator-activated Receptor Agonists
inferred← citeshttps://doi.org/10.1016/j.amjms.2017.06.011openalex-snapshot
Diabetes-Related Dyslipidemia and Cardiovascular Events
inferred← citeshttps://doi.org/10.1016/j.amjopharm.2009.08.003openalex-snapshot
Geriatric pharmacotherapy updates
inferred← citeshttps://doi.org/10.1016/j.ando.2010.02.001openalex-snapshot
The lipid triad, or how to reduce residual cardiovascular risk?
inferred← citeshttps://doi.org/10.1016/j.artere.2017.07.002openalex-snapshot
Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts
inferred← citeshttps://doi.org/10.1016/j.artere.2017.07.004openalex-snapshot
The application of atherogenic dyslipidaemia consensus recommendations in the primary care setting. DAT-AP study
inferred← citeshttps://doi.org/10.1016/j.artere.2019.02.002openalex-snapshot
Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects
inferred← citeshttps://doi.org/10.1016/j.artere.2019.12.001openalex-snapshot
Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias
inferred← citeshttps://doi.org/10.1016/j.arteri.2011.07.003openalex-snapshot
Riesgo residual vascular de origen lipídico. Estrategias para el tratamiento del riesgo residual por dislipidemia aterogénica
inferred← citeshttps://doi.org/10.1016/j.arteri.2014.04.002openalex-snapshot
Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. Cardiovascular risk perception
inferred← citeshttps://doi.org/10.1016/j.arteri.2016.12.001openalex-snapshot
Recomendaciones prácticas para el manejo del riesgo cardiovascular asociado a la dislipemia aterogénica, con especial atención al riesgo residual. Adaptación española de un Consenso Europeo de Expertos
inferred← citeshttps://doi.org/10.1016/j.arteri.2017.04.003openalex-snapshot
The application of atherogenic dyslipidaemia consensus recommendations in the primary care setting. DAT-AP study
inferred← citeshttps://doi.org/10.1016/j.arteri.2018.06.007openalex-snapshot
Riesgo cardiovascular residual de origen lipídico. Componentes y aspectos fisiopatológicos
inferred← citeshttps://doi.org/10.1016/j.arteri.2019.12.003openalex-snapshot
Triglicéridos, colesterol HDL y dislipidemia aterogénica en la guía europea para el control de las dislipidemias 2019
inferred← citeshttps://doi.org/10.1016/j.arteri.2020.12.015openalex-snapshot
Epidemiología de las hipertrigliceridemias
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2009.03.008openalex-snapshot
Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2011.01.011openalex-snapshot
Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2011.02.012openalex-snapshot
Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2011.04.020openalex-snapshot
Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2011.06.012openalex-snapshot
ESC/EAS Guidelines for the management of dyslipidaemias
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2011.06.028openalex-snapshot
ESC/EAS Guidelines for the management of dyslipidaemias
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2011.08.015openalex-snapshot
Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2015.06.012openalex-snapshot
Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: A review of the literature
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2015.07.038openalex-snapshot
Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2016.08.018openalex-snapshot
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2019.08.014openalex-snapshot
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2021.11.022openalex-snapshot
Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2023.117312openalex-snapshot
Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2025.120555openalex-snapshot
Not all fibrates are made equal: Learning from biology and clinical trials
inferred← citeshttps://doi.org/10.1016/j.atherosclerosissup.2015.02.011openalex-snapshot
Hypertriglyceridemia in an outpatient department – Significance as an atherosclerotic risk factor
inferred← citeshttps://doi.org/10.1016/j.atherosclerosissup.2017.05.001openalex-snapshot
Pitavastatin and HDL: Effects on plasma levels and function(s)
inferred← citeshttps://doi.org/10.1016/j.bbalip.2011.10.002openalex-snapshot
Serum triglycerides and risk of cardiovascular disease
inferred← citeshttps://doi.org/10.1016/j.beem.2013.11.002openalex-snapshot
Should low high-density lipoprotein cholesterol (HDL-C) be treated?
inferred← citeshttps://doi.org/10.1016/j.cca.2014.01.015openalex-snapshot
Postprandial hypertriglyceridemia as a coronary risk factor
inferred← citeshttps://doi.org/10.1016/j.ccl.2015.02.007openalex-snapshot
Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease
inferred← citeshttps://doi.org/10.1016/j.ccl.2017.12.009openalex-snapshot
Evolution of Omega-3 Fatty Acid Therapy and Current and Future Role in the Management of Dyslipidemia
inferred← citeshttps://doi.org/10.1016/j.ccol.2015.05.003openalex-snapshot
10.1016/j.ccol.2015.05.003
inferred← citeshttps://doi.org/10.1016/j.ccol.2015.05.014openalex-snapshot
10.1016/j.ccol.2015.05.014
inferred← citeshttps://doi.org/10.1016/j.cjca.2011.05.007openalex-snapshot
Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference
inferred← citeshttps://doi.org/10.1016/j.cjca.2012.03.017openalex-snapshot
Drugs Targeting High-Density Lipoprotein Cholesterol for Coronary Artery Disease Management
inferred← citeshttps://doi.org/10.1016/j.clinthera.2015.07.021openalex-snapshot
Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?
inferred← citeshttps://doi.org/10.1016/j.clinthera.2015.08.001openalex-snapshot
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
inferred← citeshttps://doi.org/10.1016/j.cmet.2021.07.001openalex-snapshot
Cardiovascular disease in diabetes, beyond glucose
inferred← citeshttps://doi.org/10.1016/j.cnd.2026.05.002openalex-snapshot
Quels traitements médicamenteux en 2025 pour réduire le risque cardiovasculaire associé à l’hypertriglycéridémie ?
inferred← citeshttps://doi.org/10.1016/j.diabet.2010.10.001openalex-snapshot
Lipids, lipid-lowering therapy and diabetes complications
inferred← citeshttps://doi.org/10.1016/j.diabres.2009.01.016openalex-snapshot
Preventing diabetic complications: A primary care perspective
inferred← citeshttps://doi.org/10.1016/j.diabres.2011.05.034openalex-snapshot
Diabetic dyslipidaemia in Asian populations in the Western Pacific Region: What we know and don’t know
inferred← citeshttps://doi.org/10.1016/j.diabres.2014.07.010openalex-snapshot
The triglycerides-to-HDL-cholesterol ratio and cardiovascular disease risk in obese patients with type 2 diabetes: An observational study from the Swedish National Diabetes Register (NDR)
inferred← citeshttps://doi.org/10.1016/j.diabres.2026.113168openalex-snapshot
Chronic complication risk and benefits of fenofibrate in type 2 diabetes by a PPARα polymorphism (rs6008845, C/T): a FIELD trial substudy
inferred← citeshttps://doi.org/10.1016/j.drudis.2017.01.006openalex-snapshot
PCSK9 and diabetes: is there a link?
inferred← citeshttps://doi.org/10.1016/j.ecl.2014.08.001openalex-snapshot
Beginning to Understand High-Density Lipoproteins
inferred← citeshttps://doi.org/10.1016/j.ecl.2015.09.012openalex-snapshot
Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease
inferred← citeshttps://doi.org/10.1016/j.ecl.2017.10.006openalex-snapshot
Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients
inferred← citeshttps://doi.org/10.1016/j.ejim.2017.07.018openalex-snapshot
Prospective study of metabolic syndrome as a mortality marker in chronic coronary heart disease patients
inferred← citeshttps://doi.org/10.1016/j.ejphar.2018.09.015openalex-snapshot
Selective peroxisome proliferator-activated receptor-α modulator K-877 regulates the expression of ATP-binding cassette transporter A1 in pancreatic beta cells
inferred← citeshttps://doi.org/10.1016/j.endien.2019.04.006openalex-snapshot
The prevalence and risk factors associated with dyslipidemia in type 2 diabetic patients in the autonomous Region of Cantabria
inferred← citeshttps://doi.org/10.1016/j.endinu.2019.04.010openalex-snapshot
Prevalencia y factores de riesgo asociados a la dislipidemia en pacientes diabéticos tipo 2 de la Comunidad de Cantabria
inferred← citeshttps://doi.org/10.1016/j.endonu.2010.05.010openalex-snapshot
¿Debemos modificar el tratamiento de la dislipemia diabética después del estudio de lípidos del Action to Control Cardiovascular Risk in Diabetes?
inferred← citeshttps://doi.org/10.1016/j.eprac.2022.08.002openalex-snapshot
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
inferred← citeshttps://doi.org/10.1016/j.eprac.2023.02.001openalex-snapshot
American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update
inferred← citeshttps://doi.org/10.1016/j.eprac.2026.01.006openalex-snapshot
American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes – 2026 Update
inferred← citeshttps://doi.org/10.1016/j.heliyon.2020.e05431openalex-snapshot
Pemafibrate, a PPAR alpha agonist, attenuates neointima formation after vascular injury in mice fed normal chow and a high-fat diet
inferred← citeshttps://doi.org/10.1016/j.hlc.2014.12.009openalex-snapshot
Clinical Guidelines on Hyperlipidaemia: Recent Developments, Future Challenges and the Need for an Australian Review
inferred← citeshttps://doi.org/10.1016/j.hlc.2016.09.005openalex-snapshot
Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes
inferred← citeshttps://doi.org/10.1016/j.ihj.2013.10.015openalex-snapshot
The nuances of atherogenic dyslipidemia in diabetes: Focus on triglycerides and current management strategies
inferred← citeshttps://doi.org/10.1016/j.ihj.2014.12.001openalex-snapshot
Consensus statement on management of dyslipidemia in Indian subjects
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2024.132903openalex-snapshot
Designing starch-based fenofibrate formulations using the melting method
inferred← citeshttps://doi.org/10.1016/j.ijcard.2016.09.081openalex-snapshot
Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East
inferred← citeshttps://doi.org/10.1016/j.jacasi.2025.12.024openalex-snapshot
Importance and Management of Non–High-Density Lipoprotein Cholesterol in Dyslipidemia Treatment
inferred← citeshttps://doi.org/10.1016/j.jacl.2010.08.004openalex-snapshot
High-density lipoprotein therapeutics and cardiovascular prevention
inferred← citeshttps://doi.org/10.1016/j.jacl.2012.02.002openalex-snapshot
Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: A pooled analysis of controlled studies
inferred← citeshttps://doi.org/10.1016/j.jacl.2012.04.003openalex-snapshot
Treatment options for the management of hypertriglyceridemia: Strategies based on the best-available evidence
inferred← citeshttps://doi.org/10.1016/j.jacl.2013.08.001openalex-snapshot
High-density lipoproteins: A consensus statement from the National Lipid Association
inferred← citeshttps://doi.org/10.1016/j.jacl.2014.08.008openalex-snapshot
Plasma triglycerides predict incident albuminuria and progression of coronary artery calcification in adults with type 1 diabetes: The Coronary Artery Calcification in Type 1 Diabetes Study
inferred← citeshttps://doi.org/10.1016/j.jacl.2016.03.008openalex-snapshot
Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia
inferred← citeshttps://doi.org/10.1016/j.jacl.2017.05.014openalex-snapshot
Pharmacologic approaches for the management of patients with moderately elevated triglycerides (150–499 mg/dL)
inferred← citeshttps://doi.org/10.1016/j.jacl.2020.04.009openalex-snapshot
The association between triglycerides and incident cardiovascular disease: What is “optimal”?
inferred← citeshttps://doi.org/10.1016/j.jchromb.2026.125028openalex-snapshot
Determination of fenofibric acid in saliva and exhaled breath condensate samples using metal- organic frameworks based dispersive micro solid phase extraction coupled to HPLC-PDA
inferred← citeshttps://doi.org/10.1016/j.jlr.2026.101050openalex-snapshot
Effects of fenofibrate on angiopoietin-like 3/4/8 proteins and apolipoprotein A5
inferred← citeshttps://doi.org/10.1016/j.mayocp.2014.06.016openalex-snapshot
A Summary and Critical Assessment of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Filling the Gaps
inferred← citeshttps://doi.org/10.1016/j.mcna.2011.11.006openalex-snapshot
Triglycerides: How Much Credit Do They Deserve?
inferred← citeshttps://doi.org/10.1016/j.mcna.2014.11.008openalex-snapshot
Management of Diabetes in the Elderly
inferred← citeshttps://doi.org/10.1016/j.medcli.2010.03.014openalex-snapshot
Riesgo vascular residual: recomendaciones de la Iniciativa Espa˜ola para la Reducción del Riesgo Residual
inferred← citeshttps://doi.org/10.1016/j.medcli.2012.09.030openalex-snapshot
Dislipemia en población diabética tratada con estatinas. Resultados del estudio DYSIS en España
inferred← citeshttps://doi.org/10.1016/j.molmed.2025.08.003openalex-snapshot
Cholesterol efflux in HIV-associated atherosclerosis: mechanisms and targets
inferred← citeshttps://doi.org/10.1016/j.numecd.2013.05.002openalex-snapshot
Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update
inferred← citeshttps://doi.org/10.1016/j.nurpra.2013.08.017openalex-snapshot
Dyslipidemia in Adults: How Recent Research and Recommendations Affect Nurse Practitioner Practice
inferred← citeshttps://doi.org/10.1016/j.orcp.2011.03.012openalex-snapshot
Fenofibrate ameliorates insulin resistance, hypertension and novel oxidative stress markers in patients with metabolic syndrome
showing the first 200 of 536 · page through all 536
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.